Navigation Links
Adamas Pharmaceuticals Initiates a Phase 2/3 Clinical Study of ADS-5102 for Parkinson's Disease
Date:9/28/2011

EMERYVILLE, Calif., Sept. 28, 2011 /PRNewswire/ -- Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has initiated a Phase 2/3 clinical trial of its proprietary investigational drug ADS-5102 (amantadine HCl extended release) for the treatment of levodopa induced dyskinesia (LID) in patients with Parkinson's disease.  Called EASED™ (Extended Release Amantadine Safety and Efficacy Study in Levodopa-Induced Dyskinesia), this study will evaluate the safety and effectiveness of three dose levels of ADS-5102 in the treatment of LID.

"Commencement of this Phase 2/3 clinical study of ADS-5102 culminates years of Adamas research into the use of amantadine as a treatment for LID in Parkinson's disease, and represents the first well controlled, rigorously powered study of amantadine aimed at licensure in this indication," said Gregory Went, Ph.D., Chief Executive Officer of Adamas.  "The EASED™ study will build upon our successful Phase 1 studies in healthy volunteers, which confirmed the desired target pharmacokinetic profile and potential tolerability improvement associated with ADS-5102."

Dr. Matthew Stern, Professor of Neurology, University of Pennsylvania, a member of Adamas' Clinical Advisory Board added, "LID represents a significant unmet need in advanced Parkinson's disease. Unfortunately there is no drug approved for this condition and patients face limited treatment options. We know that amantadine has some utility in treating LID in Parkinson's disease – but a well controlled, rigorously powered study of this drug has not been completed to date. "

EASED™ is a randomized, placebo controlled, clinical trial that will enroll up to 80 Parkinson's disease patients at approximately 25 study sites in the US.  The study's primary endpoint is reduction in LID as assessed by changes in the Unified Dy
'/>"/>

SOURCE Adamas Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Adamas Pharmaceuticals Signs CRADA With U.S. Navy to Conduct Preclinical Studies of Triple-Combination Antiviral Drug Therapy for Influenza A, Including the Novel H1N1 Pandemic Strain
2. In Vitro Study of Adamas Pharmaceuticals Triple Combination Antiviral Drug Therapy Shows Activity Against Drug-Resistant Influenza Viruses
3. Adamas Pharmaceuticals Announces In Vitro Data Demonstrating TCAD Therapy is More Potent Than Double Combinations or Monotherapy Against Drug-Resistant Flu Strains
4. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... , WESTON, Fla. , June 15 DHL ... the needs of mail-order pharmacies. DHL SMARTMAIL PHARMA SELECT ™ ... of serving the pharmaceutical industry. Thanks to this expertise and Global ... with greater accountability and value. , ...
... June 15 Solos Endoscopy, Inc. (Pink ... has developed a relay lense adapter system for its ... scope and endocoupler to join with virtually all video ... the flexibility to market the MammoView® to those customers ...
Cached Medicine Technology:DHL Global Mail Launches Specialized Shipping Service for Mail-Order Pharmacies 2Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line 2
(Date:4/18/2014)... 160 years of neuroanatomy on its head. , Myelin, ... for the fast transmission of impulses along the axons ... according to a new work lead by Professor Paola ... the University,s Department of Stem Cell and Regenerative Biology, ... of Molecular and Cellular Biology. , "Myelin is a ...
(Date:4/18/2014)... Simon Fraser University psychologists have made a brain-related ... of attention-deficit disorders. , This discovery opens up ... hinder or suppress a specific brain activity that ... distraction. , The Journal of Neuroscience ... by John McDonald, an associate professor of psychology ...
(Date:4/17/2014)... inflammation in benign prostate tissue was associated with ... was found even in those with low prostate-specific ... in Cancer Epidemiology, Biomarkers & Prevention , ... Research. , An analysis of prostate tissue biopsies ... of the Prostate Cancer Prevention Trial (PCPT) found ...
(Date:4/17/2014)... Ill. One of the most popular vaccine brands ... And doctors may be overlooking some cost factors when ... a more expensive option, according to a new study ... vaccines to administer can be driven by numerous factors," ... and a professor of computer science and of mathematics ...
(Date:4/17/2014)... 2014) Two recent papers by a University ... may help scientists develop treatments or vaccines for ... encephalitis and other disease-causing flaviviruses. , Jeffrey S. ... genetics at the School of Medicine and an ... Institute, and colleagues recently published articles in the ...
Breaking Medicine News(10 mins):Health News:Finding turns neuroanatomy on its head 2Health News:Finding turns neuroanatomy on its head 3Health News:Scientists discover brain's anti-distraction system 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2
... Drills and Anesthesia are the instruments dentists’ swear by, what ... to drill// a tooth to treat decay? While you can ... early man could have tapped, researchers have dug up the ... flint head served the purpose of a drill. ...
... one of the world’s poorest country, more than a month ... near its southern border with Nigeria. ,The semi-desert former ... areas on February 28, the day after an outbreak of ... as it lacked the resources to do the job. ...
... administering noxious substance to the patient in the hospital. The woman ... to give lethal doses of drugs to the patient. ... is a member of medical staff but not a qualified nurse. ... bail to return on Wednesday, 17 May. ,The woman, ...
... Tropical cyclone Glenda has increased the spread of the ... Western Australian regions, Kimberley and Pilbara. ,The ... that causes Murray Valley encephalitis (MVE). The cyclone Glenda ... mosquito breeding grounds. ,The Department of Health ...
... According to a recent Florida State University study, hospitals ... in IT// for all hospital operations. ,According ... hospitals, Manatee Memorial and Lakewood Ranch Medical Centre, have ... last few years. He said that, the hospitals are ...
... the medicine metformin is taken once daily it is safe ... words of co-author Dr. Bret Berner, "With this extended-release formula, ... day. The new formulation, which goes by the brand name ... ,Dr. Bret Berner is chief scientific officer and vice ...
Cached Medicine News:Health News:Delayed Start By Niger On Culling Of Poultry 2Health News:Delayed Start By Niger On Culling Of Poultry 3Health News:Technology Can Help Fight Health Care Costs 2Health News:Technology Can Help Fight Health Care Costs 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: